carvedilol has been researched along with Muscular Dystrophy, Duchenne in 4 studies
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of carvedilol for left ventricular dysfunction in Duchenne muscular dystrophy (DMD), we enrolled 8 patients with DMD who had elevated plasma atrial natriuretic peptide (ANP) or brain natriuretic peptide (BNP), and a low ejection fraction (EF < 40%) in echocardiography." | 3.71 | [Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy]. ( Matsumura, T; Miyai, I; Nozaki, S; Saito, T; Shinno, S, 2001) |
| "Heart failure is one of the most serious complications in Duchenne muscular dystrophy (DMD)." | 2.75 | Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. ( Kawai, M; Kikuchi, Y; Kuru, S; Matsumura, T; Tamura, T, 2010) |
| "Patients with Becker muscular dystrophy-related cardiomyopathy typically survive into their 30s, when they succumb to complications of cardiomyopathy or receive heart transplants." | 1.31 | Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy. ( Doing, AH; Renlund, DG; Smith, RA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barison, A | 1 |
| Aquaro, GD | 1 |
| Passino, C | 1 |
| Falorni, M | 1 |
| Balbarini, A | 1 |
| Lombardi, M | 1 |
| Pasquali, L | 1 |
| Emdin, M | 1 |
| Siciliano, G | 1 |
| Matsumura, T | 2 |
| Tamura, T | 1 |
| Kuru, S | 1 |
| Kikuchi, Y | 1 |
| Kawai, M | 1 |
| Doing, AH | 1 |
| Renlund, DG | 1 |
| Smith, RA | 1 |
| Saito, T | 1 |
| Miyai, I | 1 |
| Nozaki, S | 1 |
| Shinno, S | 1 |
1 trial available for carvedilol and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Carvedilol can prevent cardiac events in Duchenne muscular dystrophy.
Topics: Adolescent; Adult; Carbazoles; Carvedilol; Child; Chronic Disease; Heart Failure; Humans; Longitudin | 2010 |
3 other studies available for carvedilol and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Cardiac magnetic resonance imaging and management of dilated cardiomyopathy in a Duchenne muscular dystrophy manifesting carrier.
Topics: Adult; Biomarkers; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Child; Creatine Kinase; Disease | 2009 |
Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Carbazoles; Cardiomyopat | 2002 |
[Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Humans; Muscular Dystrophy, | 2001 |